Now Available For Purchase By Chapter

Chapter 1

The Thrombotic AMI Lesion: Lessons from Pathology more...

Chapter 2

Electrocardiographic Identification of the Culprit Lesion in ST-Segment Elevation Myocardial more...

Chapter 3

The Role of Thrombolysis in the Era of STEMI Interventions more...

Chapter 4

STEMI Interventions: A Review of Relevant Clinical Trials more...

Chapter 5

Updated Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction more...

You are here

$20.00
SKU: 4

Chapter 4
STEMI Interventions: A Review of Relevant Clinical Trials
Raghotham R. Patlola, MD, Craig M. Walker, MD, Michael McElderry, MD, Agostino Ingraldi, MD, Wade May, MD

Coronary artery disease is the leading cause of death in the United States. There are about 1.5 million hospital admissions annually in the U.S. with acute coronary syndromes (ACS). Nearly 1 million of these admissions are classified as unstable angina (UA)/non ST-elevation myocardial infarction (NSTEMI) and approximately 500,000 are STEMI. About 25-35% of these patients die before receiving medical attention, most often from ventricular fibrillation. However, there has been a considerable decline in mortality as a consequence of improvements in initial therapy, including fibrinolysis and percutaneous coronary intervention (PCI). Although improvements exist, time is of paramount importance for both primary PCI and thrombolytic therapy in improving survival rates.

List price: $0.00
Price: $20.00